Curatis Holding AG
/ Key word(s): AGMEGM
MEDIA RELEASE Liestal, Switzerland, 21 June 2024: Curatis Holding AG (CURN.SW), a SIX Swiss Exchange listed specialty pharmaceutical and therapeutic drug development company focused on orphan and ultra-orphan indications today held its Annual General Meeting. The shareholders of Curatis Holding AG voted in favour of all proposals of the Board of Directors and have approved all resolutions relating to the annual report and the financial year 2023 of the company, the change of auditor to Forvis Mazars, the board and management compensation as well as selected adjustments to the articles of associations with large majorities. The shareholders present (85.43% percent of voting rights) also re-elected - for a further term of 1 year - all members of the board, consisting of Marian Borovsky (Chairman, independent), Günter Graubach, Roland Rutschmann and Silvio Inderbitzin (independent). As members of the compensation committee, Marian Borovsky, Roland Rutschmann and Günter Graubach were re-elected for a term of 1 year. About the Curatis Group Investors Relations contact:
Disclaimer End of Media Release |
Language: | English |
Company: | Curatis Holding AG |
Weierweg 7 | |
4410 Liestal | |
Switzerland | |
ISIN: | CH1330780979 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1930923 |
End of News | EQS News Service |
1930923 21.06.2024 CET/CEST